OSR Health Files Appeal to Nasdaq Delisting; Trading Suspension Set Aug 26

What Happened

• OSR Health, Inc. (OSRH) announced on August 25, 2026 that it submitted a request for a hearing before a Nasdaq Hearings Panel to appeal Nasdaq’s determination to delist its common stock and warrants for failure to meet the minimum bid price requirement under Nasdaq Listing Rule 5550(a)(2).
• Because the company was previously granted a second 180‑day compliance period, the timely hearing request does not prevent the scheduled suspension of trading in OSR Health’s securities at the opening of business on August 26, 2026. The hearing request is expected to delay the filing of a Form 25‑NSE (which would formally remove the securities from Nasdaq) while the Panel considers the appeal.

Key Details

• Filing date: August 25, 2026 (8‑K reporting Item 8.01: Other Events).
• Nasdaq rule cited: Listing Rule 5550(a)(2) — minimum bid price non‑compliance.
• Compliance history: Company had been granted a second 180‑day compliance period.
• Immediate effect: Trading suspension scheduled at Nasdaq opening on August 26, 2026; formal delisting action (Form 25‑NSE) is expected to be stayed pending the Panel’s decision.

Why It Matters

• A suspension of trading will limit shareholders’ ability to buy or sell OSRH shares on Nasdaq starting Aug 26, 2026, and continued listing is uncertain until the Panel rules.
• If Nasdaq ultimately delists the securities, liquidity and access to capital could be materially affected; the company says it will present a plan at the hearing to regain and sustain compliance, but there is no assurance the Panel will accept it.
• Investors should note the procedural protections (hearing request can delay formal delisting) but also the material risks disclosed: trading suspension is imminent and continued Nasdaq listing is unresolved.